Corporate Finance Debt Deals M&A Deals Old Articles
Scramble to fend off takeover: Allergan vs. Valeant
Valeant Pharmaceuticals International; Market Cap. (as of 3/10/2014): $42.9bn Allergan Inc.; Market Cap. (as of 3/10/2014): $53.64bn As low debt obligations alongside large cash holdings and patent expiration liabilities continue to foster a conducive environment for M&A activity in the pharmaceutical and biotech industry another multi-billion dollar struggle has emerged: Read more…